Latest News and Press Releases

BASEL, Switzerland, April 3, 2007 (PRIME NEWSWIRE) -- New data presented at ECCMID highlight the microbiological and pharmacokinetic profiles of Basilea's (SWX:BSLN) two late-stage drug candidates...

BASEL, Switzerland, March 9, 2007 (PRIME NEWSWIRE) -- Further information about the press release is available on www.basilea.com. ...

BASEL, Switzerland, March 7, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) shareholders approve all Board of Directors' proposals at Annual General Meeting. Basilea's shareholders...

BASEL, Switzerland, Feb. 19, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that its placebo-controlled pivotal phase III BACH trial (Benefit of Alitretinoin in Chronic...

BASEL, Switzerland, Feb. 7, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) invites its shareholders to the Ordinary General Meeting of Shareholders to be held on Wednesday, March 7,...

BASEL, Switzerland,, Jan. 31, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced 2006 financial results reflecting successful investments in its three phase III drug candidates....

BASEL, Switzerland, Jan. 10, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that the second pivotal ceftobiprole phase III study in complicated skin infections met its...

BASEL, Switzerland, Dec. 19, 2006 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today the opening of two primary-treatment phase III clinical trials for isavuconazole (BAL8557)...

BASEL, Switzerland, Dec. 7, 2006 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that it has exercised its co-promotion option on ceftobiprole, its investigational anti-MRSA...

BASEL, Switzerland, Sept. 29, 2006 (PRIMEZONE) -- Ceftobiprole is the first anti-MRSA broad-spectrum cephalosporin to demonstrate efficacy in a large clinical trial in patients infected with...